Alveolar Macrophages: RESULTS

Percentages of Alveolar Macrophages Expressing HLA-D Region Antigens in the Different Patient Groups

HLA-DR antigens were expressed on the majority of alveolar macrophages from all patients and control subjects and there were no significant differences between the groups (Mann-Whitney U test). Similar results were obtained for expression of HLA-DQ and HLA-DP subregion products although there was greater individual variation (Table 3). A tendency toward slightly lower percentage counts of macro­phages expressing HLA-DQ and HLA-DP in the patients with FA and controls compared with patients with EAA and sarcoidosis was not significant (Mann- Whitney U test).

Intensity of Expression of HLA-D Region Antigens on Alveolar Macrophages

Although the majority of alveolar macrophages expressed HLA-D region antigens, fluorescence inten­sity measurements indicated that the amounts ex­pressed differed in the different disease groups. Figure 3a through с shows the median values of fluorescent intensity (corrected for “background” fluorescence) for HLA-DR, DQ, and DP expression on the total macrophage population of each patient in the disease groups. The control range is also indicated in each figure. kamagra oral jelly 100mg

The intensity of HLA-DR expression on alveolar macrophages was higher in EAA and sarcoidosis than in the patients with FA plus scleroderma, the total patients with FA, or the control subjects (Fig 3a). However, only the difference between EAA and the total patients with FA reached statistical significance at the p<0.05 level (Mann-Whitney U test). In addi­tion, only the levels in EAA reached a trend (p<0.1) of difference compared with the control values (me­dian, 5.6 xlO3; range 3.8-13.7 x 103; mean [±SD], 7.8 ±4.1 x 103).

FIGURE 3. Differences in intensity of expression of HLA-DR (Fig 3a), HLA-DQ (Fig 3b), HLA-DP (Fig 3c) antigens, and transferrin receptors (Fig 3d) on the total alveolar macrophage population in patients with granulomatous lung diseases (EAA = extrinsic allergic alveolitis; SARC = sarcoidosis) compared with patients having fibrosing alveolitis with or without associated connective tissue diseases (CFA = cryptogenic fibrosing alveolitis; FA + SCL = fibrosing alveolitis associated with scleroderma; FA + PBC = fibrosing alveolitis associated with primary biliary cirrhosis). NR indicates the range for controls. ‘Significant differences compared with the total patients with FA. #, Significant difference compared with FA + scleroderma (Mann-Whitney U test). NS = not significant.

HLA-DQ levels differed more strikingly between the disease groups (Fig 3b). They were significantly higher in EAA than in the total patients with FA (p<0.002), scleroderma (p<0.02), or controls (p<0.02). They were also higher in sarcoidosis than in the total patients with FA (p<0.002), scleroderma (p<0.01), or control subjects (p<0.02) (Fig 3b). The levels in the total patients with FA or scleroderma did not differ from the control values (median, 1.02 X 103; range, 0.42 — 2.19 x 103; mean [±SD], 0.99 ±0.61 x 103).

HLA-DP expression was also significantly higher in EAA (p<0.05) and sarcoidosis (p<0.02) than in the total patients with FA or scleroderma which resembled the control values (median, 2.28 xlO3; range, 1.02- 2.65 x 103; mean [ ± SD], 1.98±0.85 x 103) (Fig 3c).

Table 3—Percentages of Alveolar Macrophages Expressing HLA-D Region Antigens and Transferrin Receptors in the Different Study Groups

Group*

Transferrin Receptors

HLA-DR Mean ± SD, % (Range)

HLA-DQ

Mean ± SD, % (Range)

HLA-DP

n

Mean ± SD, % (Range)

n

Mean ± SD, % (Range)

Granulomatous

lung diseases

EAA

13

68 ± 20 (23-95)

94 ± 4 (85-98)

85 ± 9 (72-98)

4

88 ±7 (82-97)

Sarcoidosis

23

71 ±19 (14-93)

93 ± 4 (84-98)

86 ±10 (58-97)

13

86 ±12 (60-98)

Total

36

70 ±19 (14-95)

93 ± 4 (84-98)

85 ± 10 (58-98)

17

86 ±10 (60-98)

Difiuse interstitial

fibrosing lung

diseases

CFA

3

50 ± 32 (17-80)

86 ±14 (70-98)

47 ± 30 (30-82)

3

64 ±27 (46-95)

FA + scleroderma

8

67 ± 26 (14-96)

95 ± 2 (92-98)

77 ± 28 (10-95)

7

83 ±19 (39-94)

FA + PBC

1

77

95

77

1

91

Total

12

64 ± 26 (14-96)

92 ± 8 (70-98)

69 ± 29 (10-95)

11

78 ± 21 (39-95)

Controls

7

64 ± 32 (11-94)

91 ±13 (64-99)

63 ± 36 (3-95)

7

76 ±15 (64-93)

There was a significant overall correlation between the amounts of HLA-DR, DQ, and DP expressed on the alveolar macrophages of each individual, but HLA- DR and DP correlated more closely (rs = 0.77, p<0.001) than HLA-DR and DQ (r$ = 0.39, p<0.01) (Spearman Rank correlation test).

Transferrin Receptor Expression by Alveolar Macrophages

The percentages of alveolar macrophages expressing transferrin receptors were more variable in different individuals than observed for HLA-D region antigens but the ranges were similar in all the disease groups to those in the control group (Table 3). However, the intensity of transferrin receptor expression was sig­nificantly higher in the EAA group (p<0.05) and slightly higher (p<0.1) in the sarcoidosis group than in the total patients with FA (Fig 3d). The levels in these two granulomatous disease groups did not differ significantly from the control values (median, 1.25 xlO3; range, 0.79-3.83 X 103; mean [±SD] 1.58 ± 1.14 X 103) which were significantly higher than those in the total patients with FA (p<0.05). Cialis Jelly

There was a significant overall correlation (p<0.001) between the levels of transferrin receptors (median intensities) on alveolar macrophages in each individual and those of HLA-DR, DP, and DQ (Spearman Rank correlation test).